Anaemia after pamidronate administration was reported as a treatment-related adverse reaction in adults, and the Food and Drug Administration recommends that either haematocrit or haemoglobin levels be monitored in patients treated with pamidronate.3Our results show 19% of patients with a reduction in haemoglobin significant enough to be classified as anaemia.
No comments:
Post a Comment